Serum miR‐22 is a novel prognostic marker for acute myeloid leukemia

Abstract

Background It has been demonstrated that aberrant expression of serum microRNAs is potential markers for the prognostic prediction of acute myeloid leukemia (AML). However, the clinical significance of serum miR‐22 remained uncovered. In this study, we aimed to explore the potential prognostic value of serum miR‐22 for AML. Methods Blood samples were collected from 124 patients with AML and 60 healthy individuals. Serum miR‐22 level was detected by quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR), and its potential clinical value was investigated. Results Our results showed that serum miR‐22 expression was significantly downregulated in AML subjects compared to healthy controls. Serum miR‐22 levels were lowest in AML patients with M4/M5 subtypes, and low serum miR‐22 expression occurred more frequently in AML patients with higher white blood cell counts or poor cytogenetic risk. Receiver operating characteristic (ROC) analysis revealed that serum miR‐22 well differentiated AML cases from healthy controls. In addition, serum miR‐22 downregulation was closely associated with worse clinical features and shorter survival. Low serum miR‐22 expression was confirmed to be an independent predictor for overall survival and relapse‐free survival in AML patients. Moreover, the expression level of serum miR‐22 was dramatically increased following treatment. In addition, serum miR‐22 levels were significantly higher in AML patients achieving complete remission (CR) than those without CR. Conclusion Collectively, serum miR‐22 might serve as a novel and promising prognostic biomarker for AML.

Epi‐miRNAs: Modern mediators of methylation status in human cancers

“…Treatment resistance and treatment‐related toxicities remain major obstacles in the management of hematological cancer patients, highlighting the urgent need for novel molecular markers able to support precision medicine (Taylor et al, 2017). Focusing on acute myeloid leukemia (AML), decreased circulating levels of verified DNMTs regulators, miR‐217 and miR‐29a/b/c, as well as of TET demethylases‐targeting miR‐22 could efficiently discriminate AML patients from healthy controls (Gong et al, 2014; Qu et al, 2020; Yan et al, 2018). Additionally, loss of miR‐29a/b/c in bone marrow mononuclear cells and serum miR‐22 have been correlated with unfavorable clinical disease features and significantly shorter survival (Qu et al, 2020; L. J. Tang, Sun, et al, 2019; Xiong et al, 2011; Zhu et al, 2013).…”

“…Focusing on acute myeloid leukemia (AML), decreased circulating levels of verified DNMTs regulators, miR‐217 and miR‐29a/b/c, as well as of TET demethylases‐targeting miR‐22 could efficiently discriminate AML patients from healthy controls (Gong et al, 2014; Qu et al, 2020; Yan et al, 2018). Additionally, loss of miR‐29a/b/c in bone marrow mononuclear cells and serum miR‐22 have been correlated with unfavorable clinical disease features and significantly shorter survival (Qu et al, 2020; L. J. Tang, Sun, et al, 2019; Xiong et al, 2011; Zhu et al, 2013). Finally, despite the role of miR‐15a in attenuating multiple myeloma cell proliferation and drug resistance, reduced exosomal miR‐15a levels have been strongly associated with increased mortality rates, highlighting the dual role of miR‐15a in multiple myeloma molecular background and clinical management (F. Li, Xu, et al, 2015; Manier et al, 2017).…”

Association between serum lactate dehydrogenase and 60‐day mortality in Chinese Hakka patients with acute myeloid leukemia: A cohort study

“…AML is a disorder characterized by clonal proliferation derived from primitive hematopoietic stem cells or progenitor cells. 1 , 2 Abnormal differentiation of myeloid cells results in a high level of immature malignant cells and fewer differentiated red blood cells and platelets. Sixty‐day mortality is defined as a patient dying from any cause within 60 days of hospitalization with AML, 3 , 4 However, 60‐day mortality remains a significant problem and physicians have devoted much effort to avoiding it; 5 nevertheless, it has not yet been adequately addressed.…”

“…AML is a disorder characterized by clonal proliferation derived from primitive hematopoietic stem cells or progenitor cells. 1,2 Abnormal differentiation of myeloid cells results in a high level of immature malignant cells and…”